The European Commission has approved independent Swiss biotech firm Octapharma's Nuwiq (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with hemophilia A (congenital factor VIII [FVIII] deficiency).
Nuwiq is the newest generation of FVIII replacement, produced in a human cell line cultured without additives of human or animal origin, the company stated. Nuwiq is devoid of antigenic non-human protein epitopes and has a high affinity for the von Willebrand coagulation factor, both of which are potentially important properties in reducing FVIII inhibitor formation. The development of Nuwiq aimed to address the challenges of inhibitor formation as well as the frequent infusions required for prophylaxis of bleeding.
"Nuwiq represents a potential leap forward in dealing with the greatest clinical challenges in hemophilia A, FVIII inhibitors and the frequent infusions needed for bleeding prophylaxis. In clinical trials, Nuwiq demonstrated outstanding efficacy in preventing and treating bleeding in patients previously on FVIII (PTPs). No inhibitors in clinical trials in PTPs have been seen," says Olaf Walter, senior vice president of international business units.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze